Lorus Therapeutics Inc., of Toronto, appointed Kevin Buchi a director.
Nastech Pharmaceutical Co. Inc., of Bothell, Wash., appointed Gordon Brandt executive vice president of science and clinical development.
PhageTech Inc., of Montreal, elected Gervais Dionne to its board.
Pharmacopeia Inc., of Princeton, N.J., appointed Mark Emkjer president of Accelrys Inc., the company's wholly owned software subsidiary.
Pharmasset Inc., of Atlanta, appointed Abel De La Rosa senior vice president, business and scientific development.
Protiveris Inc., of Gaithersburg, Md., appointed Robert Menzi chief operating officer, Sebastian Kossek chief scientific officer, Tim Seeley vice president of engineering, Raj Prabhakar director of strategic planning and business development, Mohan Natesan director of surface chemistry and Shanxiang Shen director of proteomics and biochemistry.
QrxPharma Pty Ltd., of Brisbane, Australia, named Michael Quinn, Mike Hirshorn, George Savage, David Henderson and Gary Pace to its board.